The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Randomized phase II trial of pemetrexed/cisplatin with or without CBP501 in patients with advanced malignant pleural mesothelioma (MPM).
Lee M. Krug
Research Funding - CanBas; Lilly
Antoinette J. Wozniak
Consultant or Advisory Role - Lilly
Research Funding - CanBas; Lilly
Hedy Lee Kindler
Research Funding - CanBas
Ronald Feld
Research Funding - CanBas; Lilly
Marianna Koczywas
Research Funding - CanBas
Jose Luis Morero
Research Funding - CanBas
Cristina P. Rodriguez
Research Funding - CanBas
Helen J. Ross
Research Funding - CanBas
Julie E. Bauman
Research Funding - CanBas
Sergey V Orlov
Research Funding - CanBas
John C. Ruckdeschel
Research Funding - CanBas
Alain C. Mita
Research Funding - CanBas
Luis Fein
Research Funding - CanBas
Cristian Fernandez
Consultant or Advisory Role - CanBas
Robert Hall
Consultant or Advisory Role - CanBas
Takumi Kawabe
Employment or Leadership Position - CanBas
Stock Ownership - CanBas
Sunil Sharma
Research Funding - CanBas